<?xml version="1.0" encoding="UTF-8"?>
<ref id="R115">
 <label>115.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Thompson</surname>
    <given-names>PA</given-names>
   </name>
   <name>
    <surname>Peterson</surname>
    <given-names>CB</given-names>
   </name>
   <name>
    <surname>Strati</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies</article-title>. 
  <source>
   <italic toggle="yes">Leukemia.</italic>
  </source>
  <year>2018</year>;
  <volume>32</volume>:
  <fpage>2388</fpage>â€“
  <lpage>2398</lpage>.
  <pub-id pub-id-type="pmid">29769624</pub-id>
 </mixed-citation>
</ref>
